HCA Drops 3% Post-Earnings While Analysts Lift Targets

HCA Healthcare fell 3.4% over the past week to $449.96, a notably softer outcome than the near-flat median across its closest hospital peers, and the stock now sits below what analysts collectively think it is worth.

Within the peer group, the split after earnings season is striking. UHS dropped 4.5% on the week, and THC slid 3.8%, suggesting the hospital sector broadly absorbed some bad news. SGRY surged 50.8% over the same period, though that move is company-specific rather than a read on the sector. HCA's decline puts it toward the weaker end of its closest correlated names, though not the worst performer outright.

The options market captured the anxiety ahead of Tuesday's Q3 print, and that caution has not fully unwound. The put/call ratio closed at 0.99 on October 27, more than two standard deviations above its 20-day mean of 0.89. That is the most defensive options posture on HCA in recent memory relative to its own recent history, though still well short of the 1.33 annual high. Short interest, at 2.2% of the free float, is not a material part of this story. Borrow availability is exceptionally loose, with shares available to borrow running at roughly 15 times the current short position, and cost to borrow barely above 0.45%. Nothing in the lending market points to short-side pressure.

Analysts responded to the Q3 release by raising targets rather than retreating. Four firms moved their numbers higher on October 28. B of A Securities lifted its target from $450 to $500 while staying at Neutral. Keybanc raised to $490 from $435, maintaining Overweight. TD Cowen moved to $486 from $460, keeping its Buy rating. Baird nudged its Neutral target to $409 from $393. The consensus sits at $470.59, roughly 5% above where the stock is trading now. The direction of travel is constructive, even where the ratings are not. The bull case centres on HCA's scale across 43 domestic markets, its expanding outpatient business, and cost discipline that includes a $400 million resiliency target in FY26. The bear case is harder to dismiss: same-store revenue growth decelerated to 0.8% year over year in August from 2.7% in Q2, surgical volumes have softened, and a roughly $1.3 billion headwind from health insurance exchanges is working through the numbers. One analyst cut the 2026 adjusted EBITDA estimate to $15.75 billion from $16.0 billion. The EV/EBITDA multiple has eased slightly over the past month to 9.3x, while the PE of 14.3x reflects a business generating earnings yield in the 87th percentile of the broader market, one of the stronger value signals in the factor profile.

Ownership is dominated by two entities on the 13D register. Thomas F. Frist Jr. holds a 31.6% stake, filed as a Schedule 13D, which means the filing carries an active-investor designation. That is one of the most consequential structural facts about HCA's register. The disclosure caveat applies: the stake is as last disclosed in February 2026, and positions around the 5% threshold can change without a further filing. Frisco Holding II and Hercules Holding II together account for roughly 32% of shares in the institutional data. BlackRock held 6% as of September 30, adding a small number of shares in the period.

The next earnings event is January 22, 2027. Between now and then, the level to watch is whether the August revenue deceleration turns out to be a trough or a trend: the gap between the bull case's $4.18 billion Q4 EBITDA expectation and the revised estimates already in the market is where the stock's next meaningful move will be anchored.